Roots Analysis

T-cell immunotherapy market may be worth $30B by 2030

Friday, October 23, 2015

After the early success of Immune Checkpoint Inhibitors, T-cell immunotherapy has emerged as another innovative and potent arm of the immuno-oncology market. Characterized by features such as target specificity, adaptability and memory, T-cells have been effectively used as tools to mediate an immune response. According to a recent report by Roots Analysis, there are close to 180 therapies across various phases of development.

[Read More]